Replies to post #105028 on Biotech Values

[DewDiligence]

3M Launches TLR Modulators for Pharma Industry

http://finance.yahoo.com/news/Immune-Response-Modifiers-bw-2732568255.html?x=0&.v=1

›Thursday December 2, 2010, 11:00 am EST

ST. PAUL, Minn.--(BUSINESS WIRE)-- 3M announces the availability of immune response modifier compounds for nonvaccine use in the pharmaceutical industry. The toll-like receptor (TLR) compounds, that activate through TLR7 and TLR8, show promise for the treatment of conditions including cancer, dermatologic diseases and atopic diseases, such as allergy and asthma.

The immune response modifiers available for license broaden 3M’s existing offerings of TLR agonists for use as vaccine adjuvants by adding the option of monotherapy.

“These compounds have the potential to help patients that suffer from a variety of disease states making them a very valuable tool to the pharmaceutical industry” said Mark Tomai, PhD, Director of Vaccine Business Development at 3M Drug Delivery Systems.

…About 3M Drug Delivery Systems

3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop pharmaceuticals using 3M’s inhalation or transdermal drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities combined with regulatory guidance to help bring products to market. In-house resources, including toxicology, regulatory expertise, quality assurance, operations, and marketed product support, are available for each step of the development and commercialization process. This depth of resources is one reason why more than 50 percent of all metered-dose inhalers worldwide and 80 percent of all transdermal systems in the United States utilize 3M drug delivery technology [interesting factoid]. For more information, please visit www.3M.com/dds or call 1-800-643-8086.

About 3M Health Care

3M Health Care, one of 3M’s six major business segments, provides world-class innovative products and services to help health care professionals improve the practice, delivery and outcome of patient care in medical, oral care, drug delivery, food safety and health information markets.‹

[DewDiligence]

3M’s contribution to hospital hygiene:

http://finance.yahoo.com/news/3M-Announces-Infection-bw-573649293.html?x=0&.v=1

The Clean-Trace System detects adenosine triphosphate (ATP), a substance found in all living cells and present on any contaminated surface. Samples from high-touch surfaces in a hospital, such as bed rails, light switches or nurse call buttons, are collected using the 3M™ Clean-Trace™ ATP Surface Test. If the test picks up any organic material (ATP), it will emit light in direct proportion to the contamination level which can be read and quantified by the hand-held 3M™ Clean-Trace™ NGi Luminometer. Data collected can be uploaded to the 3M™ Clean-Trace™ Online Software which provides the users advanced data analysis with tracking and full trending capabilities including automatic report generation.

[DewDiligence]

3M launches microneedle patch for dermatology applications:

http://finance.yahoo.com/news/3M-Expands-Microreplication-bw-928370100.html?x=0&.v=1

3M Drug Delivery Systems today introduced the 3M Microchannel Skin System, a new tool that can be used by dermatologists for pretreatment of patients’ skin prior to dermatological applications and procedures. The 3M Microchannel Skin System consists of a patch with hundreds of microneedles used to create microchannels in the outermost layer of the skin with minimal discomfort for patients.

This new system consists of a snap-on handle and a sterile single-patient use microneedle patch, providing dermatologists with a simple and cost-effective tool for pretreatment. To use the product, users simply clean the area to be treated, snap the handle onto a patch, and press gently into the skin in a vertical stamping motion. The patch is then disposed. This system provides an economical, sterile option versus the existing reusable microneedle products that must be cleaned between uses.